Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135559 · ClinicalTrials.gov registry record · Phase 3
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
A Phase 3 study of Haemophilia A and B With and Without Inhibitors, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT05135559: Active Phase 3 study of Haemophilia A and B With and Without Inhibitors, sponsored by Novo Nordisk A/S.
NCT05135559 is a Phase 3 study of Haemophilia A and B With and Without Inhibitors that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 153 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05135559, a Phase 3 study of Haemophilia A and B With and Without Inhibitors, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Primary Outcome
Count of episode(s)
Conditions Studied
Interventions
- DRUG Concizumab
Study Locations (20)
Florida
- Arnold Palmer Children's Hospital - Orlando
- Nemours Child Orlando Hem/Onc. - Orlando
Georgia
- Augusta Univ/Childrens Hosp-GA - Augusta
- Memorial Health University Medical Center - Savannah
Louisiana
- Children's Hosp-New Orleans - New Orleans
- Ochsner Clinic Foundation - New Orleans
Texas
- Cook Children's Hospital-Hematology-Oncology - Fort Worth
- Texas Children's Hospital_Houston - Houston
California
- Rady Childrens Hosp San Diego - San Diego
Colorado
- University of Colorado Hospital - Aurora
Illinois
- Childrens Hospital of Chicago - Chicago
Indiana
- Indiana Hemophilia-Thromb Ctr - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2029-11-02 |
| Phase | Phase 3 |
What the registry record for NCT05135559 still lists
NCT05135559 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Haemophilia A and B With and Without Inhibitors appearing as the primary indexed condition, and to 1 intervention - of which Concizumab is the first listed.
NCT05135559 names 20 study sites across 16 states, led by Florida, Georgia, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05135559 about?
NCT05135559 is a clinical study titled "A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors". This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin wi...
What is the current status of trial NCT05135559?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2022-03-24. Estimated completion is 2029-11-02.
What conditions does trial NCT05135559 study?
This clinical trial studies the following conditions: Haemophilia A and B With and Without Inhibitors.
What interventions are being tested in trial NCT05135559?
The interventions under investigation include: Concizumab (DRUG).
Who is sponsoring clinical trial NCT05135559?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05135559 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05135559's enrollment target sits among peer trials
153 1511th of 2000 higher than 488 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI